EN

Welcome to the website of VitrOmics Healthcare Holding B.V. (VitrOmics).

VitrOmics is concentrating its efforts on the development of novel diagnostic products based on the PamChip® technology platform for application in personalized medicine. The PamChip platform is developed by VitrOmics’ daughter company PamGene. The platform is already extensively used world-wide for a variety of research applications in the academic and bio-pharmaceutical research. The next milestone for Vitromics is the development of the PamChip® platform towards use in routine diagnostics.

The PamChip® platform enables the measurement of protein activities in cells and tissue. Studies with a variety of model systems and clinical materials can be performed. PamGene’s protein activity testing applications are very advanced in the research field. Protein phosphorylation and de-phosphorylation activity measurements as well as measurements of transcriptional activity is performed. The activity of essential cellular proteins such as kinases and phosphatases are monitored. PamGene presents many examples and scientific publications on the use of the PamChip® technology platform on its website (www.pamgene.com).

Vitromics has started the validation process of the PamChip® platform as a routine diagnostic tool to support therapeutic choices on an individual basis in oncology. The first two clinical biomarker evaluation trials (breast cancer and esophageal cancer) are ongoing. The PamChip® platform is used in these studies to collect additional information on protein activities in a patient samples. This provides a complete new level of analytical information additionally to information from DNA sequencing.

VitrOmics sees an important role for the PamChip® platform to improve the choice of therapies that can be accessed for individual patients, reimbursed by health insurance companies and according to clinical guidelines. To be able to do this more finely graded diagnostic tools are needed. A better check for fit with a therapy will have at least four positive effects for the patient and healthcare system:

  1. Avoiding non-response: Non responding patients do suffer from side effects.
  2. Limiting unnecessary tumor stress:  this could have negative effects for later treatments or access to treatment options
  3. Avoiding loss of time on unnecessary treatment. Time is of essence in oncology 
  4. Limitation of opportunity loss: energy, time and money is spent on treating patients that will have no benefit from the treatment.